Bristol-Myers Squibb (NYSE:BMY) - 주가, 뉴스 및 분석

BMY 주식 개요

브리스톨-마이어스 스퀴브 컴퍼니는 전 세계에서 바이오 의약품을 발굴, 개발, 허가, 제조, 마케팅, 유통 및 판매하는 기업입니다. 자세한 내용

BMY 기본 분석
눈송이 점수
가치 평가	5/6
미래 성장	4/6
과거 실적	0/6
재무 상태	3/6
배당금	4/6

보상

공정 가치 추정치보다 낮은 67.4% 에서 거래

수익은 매년 48.75% 증가할 것으로 예상됩니다.

동종업계 및 업계 대비 좋은 가치로 거래

위험 분석

부채비율이 높네요

4.1% 의 배당금은 수익으로 잘 충당되지 않습니다.

Community Narratives

Create a narrative

Narratives bring a range of perspectives from our community.

WarrenAI

Based on Analyst Price Targets

Innovative Therapies And Calculated Moves Unlock New Growth Horizons In Pharmaceuticals

Key Takeaways Launch of innovative treatments is poised to drive future revenue by addressing large unmet needs and expanding market presence in various disorders. Strategic acquisitions and a cost savings program aim to enhance growth and net margins through innovation and operational efficiency.

View narrative

US$58.64

0.2% undervalued

-2.07%

Revenue growth p.a.

Updated

Bristol-Myers Squibb Company 경쟁사

Zoetis

NYSE:ZTS

US$79.9b

Pfizer

NYSE:PFE

US$151.4b

Merck

NYSE:MRK

US$249.2b

Johnson & Johnson

NYSE:JNJ

US$368.9b

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Bristol-Myers Squibb
과거 주가
현재 주가	US$58.50
52주 최고치	US$61.08
52주 최저치	US$39.35
베타	0.44
11개월 변경	10.88%
3개월 변경 사항	18.52%
1년 변경 사항	15.07%
33년 변화	-0.91%
5년 변화	2.90%
IPO 이후 변화	2,637.84%

최근 뉴스 및 업데이트

Bristol-Myers Squibb Deserves Its Place Among Its Big Pharma Brethren

Oct 28

Recent updates

Bristol-Myers Squibb Company's (NYSE:BMY) Share Price Is Matching Sentiment Around Its Revenues

Aug 15

Bristol-Myers Squibb: A Potential Comeback In Healthcare

Aug 06

Bristol-Myers Squibb: Q2 Earnings Look Like An Inflection Point

Jul 27

Bristol Myers Squibb: The More It Drops, The More I Buy

Jul 16

Is Bristol-Myers Squibb (NYSE:BMY) A Risky Investment?

Jun 13

Bristol Myers: Quality Fundamentals Suppressed By Interest Rates

Jun 09

Bristol-Myers Squibb: Looking Beyond The One-Time Quarterly Loss

Jun 03

Bristol-Myers Squibb: 5.5% Yielder Has Been Crushed In What Could Be A Generational Buying Opportunity

May 23

Bristol-Myers Squibb: A Lost Decade?

May 03

Lacklustre Performance Is Driving Bristol-Myers Squibb Company's (NYSE:BMY) Low P/S

Apr 29

Is Bristol Myers Squibb A Buy At These Bottom Levels?

Apr 22

Bristol Myers Squibb: Seriously Undervalued At Peak Pessimism (Rating Upgrade)

Apr 12

Bristol-Myers Squibb Is A Speculative Buy On Price Action (Technical Analysis)

Apr 02

Bristol-Myers Squibb (NYSE:BMY) Is Due To Pay A Dividend Of $0.60

Mar 21

Bristol-Myers Squibb Is Not A Buy For Me

Mar 19

Bristol-Myers Squibb: Compelling Value From The New Products Portfolio And 4.5% Yield

Mar 07

Bristol-Myers Squibb (NYSE:BMY) Is Due To Pay A Dividend Of $0.60

Mar 07

주주 수익률

	BMY	US Pharmaceuticals	US 마켓
7D	6.9%	-1.9%	-0.5%
1Y	15.1%	13.2%	32.3%

수익률 대 산업: BMY 지난 1년 동안 13.2 %를 반환한 US Pharmaceuticals 산업을 초과했습니다.

수익률 대 시장: BMY 지난 1년 동안 32.3 %를 반환한 US 시장보다 저조한 성과를 냈습니다.

가격 변동성

Is BMY's price volatile compared to industry and market?
BMY volatility
BMY Average Weekly Movement	4.3%
Pharmaceuticals Industry Average Movement	9.6%
Market Average Movement	6.2%
10% most volatile stocks in US Market	15.6%
10% least volatile stocks in US Market	3.0%

안정적인 주가: BMY 는) 지난 3개월 동안 큰 가격 변동성이 없었습니다.

시간에 따른 변동성: BMY 의 주간 변동성( 4% )은 지난 1년 동안 안정적인 모습을 보였습니다.

회사 소개

설립	직원	CEO	웹사이트
1887	34,100	Chris Boerner	www.bms.com

브리스톨-마이어스 스퀴브 컴퍼니는 전 세계에서 바이오 의약품을 발견, 개발, 허가, 제조, 마케팅, 유통 및 판매하는 회사입니다. 혈액학, 종양학, 심혈관계, 면역학, 섬유성 및 신경과학 질환을 위한 제품을 제공합니다. 주요 제품으로는 비판막성 심방세동 환자의 뇌졸중/전신색전증 위험 감소 및 심부정맥혈전증/폐색전증 치료를 위한 엘리퀴스, 방광, 혈액, CRC, 두경부암, RCC, 간암, 폐암, 흑색종, MPM, 위암 및 식도암 등 다양한 항암 적응증을 위한 옵디보 등이 있습니다; 다발성 골수종 치료제 포말리스트/이노비드, 활동성 류마티스 관절염 및 건선성 관절염 치료제 오렌시아, 필라델피아 염색체 양성 만성 골수성 백혈병 치료제 스프라이셀 등을 공급하고 있습니다.

Bristol-Myers Squibb Company 기본 사항 요약

Bristol-Myers Squibb 의 수익과 매출은 시가총액과 어떻게 비교하나요?
BMY 기본 통계
시가총액	US$118.47b
수익(TTM)	-US$7.26b
수익(TTM)	US$47.44b

2.5x

P/S 비율

-16.3x

P/E 비율

BMY 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
BMY 손익 계산서(TTM)
수익	US$47.44b
수익 비용	US$11.44b
총 이익	US$35.99b
기타 비용	US$43.25b
수익	-US$7.26b

최근 보고된 수익

Sep 30, 2024

다음 수익 날짜

Feb 06, 2025

주당 순이익(EPS)	-3.58
총 마진	75.87%
순이익 마진	-15.30%
부채/자본 비율	289.5%

BMY 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

배당금

4.1%

현재 배당 수익률

-67%

지급 비율

BMY 주식 개요

보상

위험 분석

Innovative Therapies And Calculated Moves Unlock New Growth Horizons In Pharmaceuticals

Bristol-Myers Squibb Company 경쟁사

NYSE:ZTS

US$79.9b

NYSE:PFE

US$151.4b

NYSE:MRK

US$249.2b

NYSE:JNJ

US$368.9b

가격 내역 및 성능

최근 뉴스 및 업데이트

Price target increased by 7.4% to US$58.64

Bristol-Myers Squibb Company Showcases the Continued Strength of Its Cardiovascular Portfolio with New Clinical and Real-World Data At American Heart Association Scientific Sessions 2024

Bristol Myers Squibb Presents New Long-Term Data from the EMERGENT Program Evaluating Covenfy in Adults with Schizophrenia At Psych Congress 2024

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Bristol Myers Squibb to Present New Clinical and Health Economics and Outcomes Research Data At Psych Congress 2024

Bristol-Myers Squibb Deserves Its Place Among Its Big Pharma Brethren

Recent updates

Price target increased by 7.4% to US$58.64

Bristol-Myers Squibb Company Showcases the Continued Strength of Its Cardiovascular Portfolio with New Clinical and Real-World Data At American Heart Association Scientific Sessions 2024

Bristol Myers Squibb Presents New Long-Term Data from the EMERGENT Program Evaluating Covenfy in Adults with Schizophrenia At Psych Congress 2024

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Bristol Myers Squibb to Present New Clinical and Health Economics and Outcomes Research Data At Psych Congress 2024

Bristol-Myers Squibb Deserves Its Place Among Its Big Pharma Brethren

Bristol-Myers Squibb: A High-Yield Bargain With Growth On The Horizon

U.S. Food and Drug Administration Approves Perioperative Treatment of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Single-Agent Opdivo for Resectable Non-Small Cell Lung Cancer (NSCLC)

Bristol Myers Squibb Presents New Data from Two Trials Demonstrating Sotyktu (Deucravacitinib) Efficacy in Both Moderate-To-Severe Scalp Psoriasis and in A Real-World Setting

Upcoming dividend of US$0.60 per share

Bristol-Myers Squibb: Cobenfy Approval A Major Coup For The Dealmaker (Upgrade)

U.S. Food and Drug Administration Approves Bristol Myers Squibb's COBENFY (xanomeline and Trospium Chlorx), a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults

Bristol Myers Squibb Announces New Long-Term Zeposia (ozanimod) Data Demonstrate Durable Efficacy and Consistent Safety in Relapsing Forms of Multiple Sclerosis

Bristol Myers Squibb Presents Landmark 10-Year Follow-Up Data from Checkmate -067 Which Showed Continued Durable Long-Term Survival Benefit with Opdivo® Plus Yervoy® in Advanced Melanoma

Second quarter dividend of US$0.60 announced

Bristol-Myers Squibb Company to Report Q3, 2024 Results on Oct 31, 2024

Bristol-Myers Still A Value Play Despite Appreciating 26.56% From 2024 Lows

Bristol Myers Squibb Announces Long-Term Follow-Up Data from Phase 3 Study of CAMZYOS (Mavacamten) Underscores Established Efficacy and Safety Profile in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

Bristol Myers Squibb Receives U.S. Food and Drug Administration sBLA Acceptance for First-Line Treatment of Unresectable Hepatocellular Carcinoma

European Medicines Agency Validates Bristol Myers Squibb's Application for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma

Bristol-Myers Squibb Company's (NYSE:BMY) Share Price Is Matching Sentiment Around Its Revenues

Bristol-Myers Squibb: A Potential Comeback In Healthcare

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Bristol-Myers Squibb: Q2 Earnings Look Like An Inflection Point

Consensus EPS estimates fall by 18%

Bristol-Myers Squibb Company Announces Intangible Asset Impairment Charges for the Three Months Ended June 30, 2024

Bristol Myers Squibb Receives European Medicines Agency Validation of Application for Opdivo (Nivolumab) Plus Yervoy (Ipilimumab) for First-Line Treatment of Unresectable or Advanced Hepatocellular Carcinoma

Bristol Myers Squibb: The More It Drops, The More I Buy

Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI®? (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)

Bristol-Myers Squibb Company to Report Q2, 2024 Results on Jul 26, 2024

First quarter dividend of US$0.60 announced

Bristol Myers Squibb Appoints Michael R. McMullen as Independent Director and Member of the Audit Committee, Effective July 1, 2024

Bristol Myers Squibb Declares A Quarterly Dividend, Payable on August 1, 2024

Is Bristol-Myers Squibb (NYSE:BMY) A Risky Investment?

Bristol Myers: Quality Fundamentals Suppressed By Interest Rates

Bristol Myers Squibb Announces Opdivo (Nivolumab) Plus Yervoy (Ipilimumab) Significantly Improved Overall Survival Compared to Lenvatinib or Sorafenib as First-Line Treatment for Patients with Advanced Hepatocellular Carinoma in Checkmate -9DW Trial

Bristol Myers Squibb’S Breyanzi Demonstrates Clinically Meaningful Outcomes Across Broad Range of B-Cell Malignancies in New Data Presented At 2024 Asco® Annual Meeting

Bristol-Myers Squibb: Looking Beyond The One-Time Quarterly Loss

U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Breyanzi as a New CAR T Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma

Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) in Combination with Cisplatin and Gemcitabine

Bristol-Myers Squibb: 5.5% Yielder Has Been Crushed In What Could Be A Generational Buying Opportunity

Bristol Myers Squibb Announces New Four-Year Results from the POETYK PSO Long-Term Extension Trial of Sotyktu (Deucravacitinib) Treatment in Adult Patients with Moderate-To-Severe Plaque Psoriasis

Bristol Myers Squibb's CAR T Cell Therapy Breyanzi Approves by the U.S. Food and Drug Administration for Relapsed or Refractory Follicular Lymphoma

Bristol Myers Squibb Provides Update on Phase 3 CheckMate -73L Trial

U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Application for Subcutaneous Nivolumab (nivolumab and hyaluronidase)

European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer

Bristol-Myers Squibb: A Lost Decade?

Lacklustre Performance Is Driving Bristol-Myers Squibb Company's (NYSE:BMY) Low P/S

CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb's Opdivo (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Is Bristol Myers Squibb A Buy At These Bottom Levels?

Bristol Myers Squibb: Seriously Undervalued At Peak Pessimism (Rating Upgrade)

Consensus EPS estimates fall by 24%

Bristol Myers Squibb Announces KRAZATI (adagrasib) in Combination with Cetuximab Demonstrates Clinically Meaningful Activity as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)

U.S. Fda Approves Bristol Myers Squibb and 2Seventy Bio’S Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy

European Commission Expands Approval of Bristol Myers Squibb’S Reblozyl® (Luspatercept)

Bristol-Myers Squibb Is A Speculative Buy On Price Action (Technical Analysis)

Bristol Myers Squibb Provides Update on the First Phase 3 YELLOWSTONE Trial Evaluating Oral Zeposia (Oozanimod) in Patients with Moderate to Severe Active Crohn's Disease